🏢
🌐 Entity
Olanzapine/samidorphan
Combination drug
📊 Rating
1 news mentions · 👍 0 likes · 👎 0 dislikes
📌 Topics
- Finance (1)
- Biotechnology (1)
- Healthcare (1)
🏷️ Keywords
Mizuho Securities (1) · Alkermes (1) · stock price target (1) · biopharmaceutical (1) · drug portfolio (1) · Lybalvi (1) · Vivitrol (1) · investment analysis (1)
📖 Key Information
Olanzapine/samidorphan, sold under the brand name Lybalvi, is a fixed-dose combination medication for the treatment of schizophrenia and bipolar I disorder. It contains olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist. Samidorphan reduces the weight gain associated with olanzapine while still allowing olanzapine to exert its therapeutic effect.
📰 Related News (1)
🔗 Entity Intersection Graph
People and organizations frequently mentioned alongside Olanzapine/samidorphan:
-
🌐
Alkermes · 1 shared articles
-
Naltrexone · 1 shared articles -
Mizuho Securities · 1 shared articles